VRDN · NASDAQ · STOCK
Viridian Therapeutics (VRDN) Stock Analysis
$18.68
52W $13.18 – $34.29
54/100
$2.11B
-5.3
0.96
Is VRDN Bullish or Bearish?
Mixed.
Innellis AI committee rates Viridian Therapeutics, Inc. (VRDN) Watch with a composite score of 54/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +5.86 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -14.14 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 23220.3% YoY -- genuine top-line momentum — Growth
- Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 4.1x prices in significant intangible value — Value
- ROE of only -61.4% -- cheap may mean cheap for a reason — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
54/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 71%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 4.1x prices in significant intangible value
Growth Analyst
bullish
60
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 23220.3% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bearish
39
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− Price structure making lower highs and lower lows
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock
− Bollinger bandwidth of 28.8% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
60
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
− No news coverage in the last 14 days -- limited independent confirmation either way
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 53.1 to 54.1.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: score 33->39 (+6).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
34.1
Neutral
MACD Histogram
-0.226
Bearish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$15.71
Resistance
$19.90
Bollinger %B
0.20
Inside Bands
Price vs Moving Averages
EMA 9
$19.10
Below
EMA 21
$20.16
Below
EMA 50
$20.79
Below
EMA 200
$21.18
Below
Fundamental Analysis
Valuation
92
Growth
52
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-5.3×
P/B Ratio
3.04×
PEG Ratio
-0.59
Dividend Yield
0.00%
52W High
$34.29
52W Low
$13.18
Quality & Growth
ROE
-4744.1%
ROA
-3809.1%
Gross Margin
9955.0%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.37
AI Fundamental Assessment
P/E ratio of -5.3 (inexpensive relative to a 15-40x range); Price-to-book of 3.0x; PEG ratio of -0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -47.4%; Return on assets of -38.1%; Net margin of -544.1%; Gross margin of 99.6%; Current ratio of 16.95 (healthy short-term liquidity); Debt-to-equity of 0.37; Free cash flow per share is negative (-3.11); Most recent quarter missed estimates by 0.0%; EPS growth decelerating (+16.7% -> -16.7% QoQ); Analyst estimates rising over recent quarters
Get the Full VRDN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →